All In Biotech

Drug Trial Radar · NCT04517149

4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)

An Open-label, Phase 1/2 Trial of Gene Therapy 4D-125 in Males With X-linked Retinitis Pigmentosa (XLRP) Caused by Mutations in the RPGR Gene

Last checked: Nov 20, 2026Latest source record: Mar 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

21

Actual

Start

Jun 9, 2020

Primary completion

Jun 2026

Study completion May 2029

Sponsor

Lead sponsor
4D Molecular TherapeuticsIndustry
Sponsor type
Industry
First posted
Aug 18, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2 multicenter study with two parallel parts: an observational natural history cohort and an open-label, prospective interventional trial in males with non-syndromic X-linked retinitis pigmentosa (XLRP) due to mutations in the gene encoding retinitis pigmentosa GTPase regulator (RPGR).

Conditions

  • X-Linked Retinitis Pigmentosa

Interventions

  • 4D-125 IVT InjectionBiological

    4D-125 drug product developed for gene therapy, which comprises an AAV capsid variant (4D-R100) carrying a codon-optimized human Retinitis Pigmentosa GTPase Regulator transgene.

  • ObservationalOther

    Natural History

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of TEAEs and serious adverse events (SAEs), including clinically significant changes in safety parametersTime frame: 24 months to 60 Months

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • University of Colorado

    Aurora, Colorado

  • Vitreo Retinal Associates

    Gainesville, Florida

  • University of Michigan Kellogg Eye Center

    Ann Arbor, Michigan

  • Columbia University Medical Center/Edward Harkness Eye Institute

    New York, New York

  • Duke University Eye Center/Dept. of Ophthalmology

    Durham, North Carolina

  • Casey Eye Institute, Oregon Health and Science University

    Portland, Oregon

  • Retina Foundation of the Southwest

    Dallas, Texas

  • University of Utah John A. Moran Eye Center

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.